News stories about Agios Pharmaceuticals (NASDAQ:AGIO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Agios Pharmaceuticals earned a news impact score of 0.15 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.9708453371475 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- ValuEngine Upgrades Agios Pharmaceuticals (AGIO) to “Hold” (americanbankingnews.com)
- Agios Pharmaceuticals (AGIO) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- How Analysts View Agios Pharmaceuticals and Peers in March 2018 (finance.yahoo.com)
- An Insight into Agios Pharmaceuticals’ Product Pipeline (finance.yahoo.com)
- Exploring Agios Pharmaceuticals’ Cash Flows (finance.yahoo.com)
A number of equities analysts recently issued reports on AGIO shares. Oppenheimer restated a “buy” rating and set a $83.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, December 11th. Cann restated a “buy” rating on shares of Agios Pharmaceuticals in a report on Tuesday, December 5th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, December 12th. BidaskClub cut Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, December 16th. Finally, Royal Bank of Canada boosted their price objective on Agios Pharmaceuticals to $91.00 and gave the company an “outperform” rating in a report on Thursday, January 18th. They noted that the move was a valuation call. Four equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $85.50.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The firm had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $12.65 million. During the same quarter in the prior year, the company posted ($1.34) earnings per share. Agios Pharmaceuticals’s quarterly revenue was down 56.7% compared to the same quarter last year. sell-side analysts predict that Agios Pharmaceuticals will post -6.25 earnings per share for the current fiscal year.
In other Agios Pharmaceuticals news, insider Christopher Bowden sold 2,000 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.75, for a total value of $157,500.00. Following the completion of the sale, the insider now directly owns 2,881 shares in the company, valued at approximately $226,878.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $65.00, for a total value of $195,000.00. Following the completion of the sale, the insider now owns 56,059 shares of the company’s stock, valued at $3,643,835. The disclosure for this sale can be found here. Insiders sold a total of 200,030 shares of company stock valued at $15,489,238 over the last quarter. Company insiders own 5.43% of the company’s stock.
WARNING: “Agios Pharmaceuticals (AGIO) Receives News Sentiment Rating of 0.15” was posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.wkrb13.com/2018/04/01/agios-pharmaceuticals-agio-receives-news-sentiment-rating-of-0-15.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.